Generic placeholder image

CNS & Neurological Disorders - Drug Targets


ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Case Report

Clozapine in a Young Female with Drug-Resistant Schizophrenia: A Case Report of Development of Serositis

Author(s): Andrea Aguglia*, Valentina Maria Parisi, Gabriele Arduino, Andrea Amerio, Alessandra Costanza, Gianluca Serafini and Mario Amore

Volume 22, Issue 2, 2023

Published on: 29 April, 2022

Page: [313 - 316] Pages: 4

DOI: 10.2174/1871527321666220324121207

Price: $65


Background: Clozapine may be considered the first-line option for treatment-resistant schizophrenia (TRS), a condition that occurs in more than 30% of patients with schizophrenia. Despite its efficacy for treating TRS, clozapine use is limited by the occurrence of several adverse effects in more than 70% of cases. Clozapine does not typically affect lung function, although a few cases have been reported in the literature.

Case Presentation: To gain a better understanding of this rare event, here we report the case study of a young female with TRS, who was treated with clozapine and developed medium and bilateral pleural effusion relief with contiguous atelectasis and polyserositis. Two weeks after stopping clozapine, the follow-up chest scan showed complete remission of the pulmonary condition. We postulate that clozapine might have caused, in this case, a specific immunoinflammatory response leading to serosal complications.

Conclusion: Although the underlying mechanisms of this adverse effect are not completely understood, early manifestations, such as benign eosinophilia, fever, and flu-like symptoms need to be considered a potential warning to facilitate an early diagnosis and carefully manage pulmonary complications related to clozapine treatment.

Keywords: Schizophrenia, serositis, clozapine, side effects, case report, Treatment-Resistant Schizophrenia (TRS).

« Previous

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy